Hög biologisk ålder kopplas till ökad risk för demens och stroke

Människor åldras i olika takt, som bekant. Nu indikerar en studie vid Karolinska institutet att personer med högre biologisk ålder än deras faktiska ålder löper...

The FDA’s new transparency policy (Part 3)

As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

Lundbeck behind the first EU-approved intravenous migraine treatment

A preventive, intravenous treatment for migraines has been approved in the EU for the first time.

Pfizer stämmer Novo Nordisk i miljardstrid om biotechbolag

Budstriden om Metsera trappas upp när Pfizer stämmer både det amerikanska bioteknikbolaget och Novo Nordisk. Kärnfrågan är om Novos bud på 8,5 miljarder dollar ...

New features in ZEISS CALYPSO 2024

ZEISS CALYPSO is your universal software for dimensional metrology applications.

Ozempic may benefit hip replacement surgery

The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a new study suggests....

Senzime tar in kapital för fortsatt kommersiell expansion

Medtechbolaget Senzime har beslutat att genomföra en riktad nyemisson. Bolaget planerar att ta in cirka 86 miljoner kronor.

Valves with piezo technology

Efficient control and regulation of gases in medical technology

When carelessness, forgetfulness and coincidence become the researcher’s best friend

Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advanc...

Richard Philipson ny CMO på Hansa – hämtas från Calliditas

Hansa Biopharma har rekryterat Richard Philipson till ny Chief Medical Officer (CMO). Han tillträder den 14 juli.

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Nytt grönt ljus för Tremfya – ska ersätta storsäljaren Stelara

Johnson & Johnsons Tremfya får ytterligare ett FDA-godkännande. Därmed fortsätter läkemedelsjätten förverkliga sin plan om att ersätta den tidigare storsäljaren Stelara.

Hello Jenni Nordborg!

Life Science Sweden would like to know more about Jenni Nordborg and asks her about her new job, why she became a chemical engineer and who her role model is.

Suing the company – for NOT developing a new HIV drug

Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...

Flemingsberg – en växande nod för Life Science

Flemingsberg i södra Stockholm har länge varit hem för ett livskraftigt life science-kluster. Nu sker en tydlig acceleration då fler företag etablerar sig, sama...

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Nya notan för Purdue Pharma – skandalbolaget bakom opioidkrisen

Slutnotan kan vara på väg för läkemedelstillverkaren Purdue Pharmas inblandning i USA:s opioidkris – och den ser ut att landa på minst 7,4 miljarder dollar, mot...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

Elicera develops CAR-T against solid tumours – may become the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work agains...

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...

Astra Zenecas nya viktminskningsbolag ska bevara muskelmassa

Astra Zeneca har fullföljt en option att köpa det schweiziska start up-bolaget Sixpeaks Bio, som utvecklar fetmabehandlingar.

Raise-In AB